ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 62

Convergence of Joint Repair and Pain Pathways Via Nerve Growth Factor and p75 Expressing Mesenchymal Stem Cells in Established Osteoarthritis

Thomas Baboolal1, Sumaiya Al Hinai2, Elena Jones2, Jill Reckless3, Martyn Foster4, Rachel Doyle5, Kerry af Forselles4, Simon Westbrook4 and Dennis McGonagle2, 1PhD, Leeds, United Kingdom, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 3Rxcelerate Ltd, Cambridge, United Kingdom, 4Levicept Ltd, Ramsgate, United Kingdom, 5Tetrad Discovery Ltd, Ramsgate, United Kingdom

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Bone, cartilage, Mesenchymal stem cells, osteoarthritis and pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Biology and Pathology of Bone and Joint Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Nerve growth factor (NGF) is a key regulator of pain and anti-NGF therapy reduces osteoarthritis (OA) associated pain. However, anti-NGF therapy is associated with rapidly progressive OA (RPOA) [1]. In hip OA there is a 5-fold increase in mesenchymal stem cells (MSCs) from MRI bone marrow (BM) lesions, areas associated with OA progression [2]. MSCs in such lesions are uniformly positive for the NGF receptor, p75, which is also linked to chemotaxis and proliferation in other stromal cell compartments [3]. We therefore sought to evaluate anti-NGF treatment in monoiodoacetate (MIA) induced OA and test whether NGF influences human BM- MSC function.

Methods:

Human tibial plateau (TP) bone was isolated from patients undergoing total knee replacement. OA was induced in male Wistar rats (n=6) by intra-articular injection of 0.3 mg MIA. Each animal was treated with subcutaneous injection of control human IgG or anti-NGF (3 mg/kg) on Days 30, 35, 39, 45 and 50. Human and animal tissues sections were prepared for histological analysis using H&E staining and immunohistochemistry (IHC) using anti-p75 and anti-NGF antibodies. BM-MSCs were isolated from iliac crest aspirates and cultured under normal conditions. Expression of p75 was induced following overnight incubation with 400mM ethanol (EtOH) and confirmed by flow cytometry. Proliferation and chemotaxis was assessed with and without induction of p75 and in the presence of 0-1 μg/ml NGF.

Results:

Regions adjacent to cartilage loss in human TP showed abundant stromal proliferation, NGF and p75 immunoreactivity. In the MIA model, by Day 28 there was substantial loss of cartilage, bone remodelling and stromal proliferation mimicking human disease and animals demonstrated unequal weight-bearing (p<0.05). Anti-NGF provided sufficient analgesia to normalise weight-bearing by Day 42. Features associated with joint damage and MIA treatment such as fibrogranular reactions and palisading osteoblasts were strongly p75 immunopositive. NGF positive staining was widespread in naïve and MIA-injected knees. To investigate increased p75 positivity in knee OA, we restored p75 expression loss in expanded cell, to 97% of BM-MSCs (n=3) using EtOH. Increased MSC proliferation was seen at Days 6 and 9 (26%, p=0.03 and 30%, p=0.01 increase respectively, n=7) for 1 μg/ml NGF in the presence of EtOH compared to control (no NGF). In cultures without EtOH induction (absent p75) NGF had no effect. NGF was not chemotactic for MSCs with or without the induction of p75.

Conclusion:

TP bone from OA patients and rat MIA-treated subchondral bone contains p75 positive staining in regions of cartilage destruction and associated NGF positivity. In vitro, NGF increased BM-MSC proliferation, suggesting NGF may be involved in the stromal proliferation seen at sites of OA damage. Thus, NGF may regulate MSC function. Complete blockade represents a novel mechanism for accelerated joint destruction in OA.

Reference:

1. Hochberg MC et al. Arthritis Rheumatol 2016;68:382–91. 2.Campbell TM et al Arthritis Rheumatol 2016 Jul;68(7):1648-59. 3. Jiang Y, Hu C, Yu S, et al. Cartilag Arthritis Res Ther 2015;:1–13.


Disclosure: T. Baboolal, None; S. Al Hinai, None; E. Jones, None; J. Reckless, None; M. Foster, Levicept Ltd, 5; R. Doyle, None; K. af Forselles, None; S. Westbrook, Levicept Ltd, 1,Levicept Ltd, 3; D. McGonagle, None.

To cite this abstract in AMA style:

Baboolal T, Al Hinai S, Jones E, Reckless J, Foster M, Doyle R, af Forselles K, Westbrook S, McGonagle D. Convergence of Joint Repair and Pain Pathways Via Nerve Growth Factor and p75 Expressing Mesenchymal Stem Cells in Established Osteoarthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/convergence-of-joint-repair-and-pain-pathways-via-nerve-growth-factor-and-p75-expressing-mesenchymal-stem-cells-in-established-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/convergence-of-joint-repair-and-pain-pathways-via-nerve-growth-factor-and-p75-expressing-mesenchymal-stem-cells-in-established-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology